Market Access MAPs, EAPs, and patient access: Suzanne Aitken on the challe... Suzanne Aitken, SVP of managed access at Clinigen, discussing the role of managed access programmes in the current pharmaceutical landscape.
White Papers Sponsored Thinking niche: the challenge of pharma's focus on small pat... With the pharma industry putting the ‘blockbuster’ age behind it and moving into meeting needs across myriad niche disease areas, what is the impact and therefore change of requirement in terms of
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.